Acute respiratory distress syndrome
Conditions
Interventions
Observation group:Conventional therapy combined with Sivelestat Sodium for Injection
Control Group:Conventional therapy
Sponsors
Wenjiang District People's Hospital, Chengdu
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. 18 years old< = age<=80 years old, gender is not limited; 2. Admission diagnosis of ARDS, ARDS meets the 2023 global new diagnostic criteria (Appendix 1); 3. Sign the informed consent form and fully understand the research content, process and possible adverse reactions;
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women and children; 2. Patients with malignant tumors; 3. Patients with cardiogenic pulmonary edema, patients with pneumothorax, bronchopleural fistula and severe pulmonary fibrosis; 4. Patients who are participating in other exploratory clinical studies at the same time; 5. Expected survival time not more than 5 days; 6. Allergic to the active ingredients of the experimental drug or its excipients; 7. Patients with severe data loss; 8. Patients who are judged by the investigator to be unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PaO2/FiO2;28-day survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| C-reactive protein;Procalcitonin;Interleukin-6;Duration of mechanical ventilation (MV duration);ICU length of stay (ICU LOS); | — |
Countries
China
Contacts
Public ContactLuo Linjie
Wenjiang District People's Hospital, Chengdu
Outcome results
None listed